AstraZeneca and Merck detailed results from the Phase 3 SOLO-1 trial testing Lynparza 300 mg tablets twice daily as a maintenance treatment for patients with newly-diagnosed advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. Results of the trial confirm the statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for…
AstraZeneca, Merck Obtain Orphan Drug Designation for Lynparza for Pancreatic Cancer
AstraZeneca and Merck announced that the FDA granted orphan drug designation (ODD) for Lynparza for the treatment of pancreatic cancer. Lynparza is currently being investigated as maintenance therapy in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer whose disease has not progressed following first-line platinum-based chemotherapy. Pancreatic cancer is a rare, life-threatening disease that accounts for about 3…